MA53986A - Traitement de maladies neurologiques avec du zilucoplan - Google Patents

Traitement de maladies neurologiques avec du zilucoplan

Info

Publication number
MA53986A
MA53986A MA053986A MA53986A MA53986A MA 53986 A MA53986 A MA 53986A MA 053986 A MA053986 A MA 053986A MA 53986 A MA53986 A MA 53986A MA 53986 A MA53986 A MA 53986A
Authority
MA
Morocco
Prior art keywords
zilucoplan
treatment
neurological diseases
neurological
diseases
Prior art date
Application number
MA053986A
Other languages
English (en)
Inventor
Petra Duda
Ramin Farzaneh-Far
Zhong Ma
Alonso Ricardo
Evan Thackaberry
Nanqun Zhu
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of MA53986A publication Critical patent/MA53986A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/322—Retractable needles, i.e. disconnected from and withdrawn into the syringe barrel by the piston
    • A61M5/3234—Fully automatic needle retraction, i.e. in which triggering of the needle does not require a deliberate action by the user
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Anesthesiology (AREA)
  • Physics & Mathematics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
MA053986A 2018-10-22 2019-10-22 Traitement de maladies neurologiques avec du zilucoplan MA53986A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862748659P 2018-10-22 2018-10-22
US201862777524P 2018-12-10 2018-12-10
US201962815575P 2019-03-08 2019-03-08
US201962837974P 2019-04-24 2019-04-24
US201962844388P 2019-05-07 2019-05-07
US201962899864P 2019-09-13 2019-09-13

Publications (1)

Publication Number Publication Date
MA53986A true MA53986A (fr) 2022-01-26

Family

ID=68696508

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053986A MA53986A (fr) 2018-10-22 2019-10-22 Traitement de maladies neurologiques avec du zilucoplan

Country Status (13)

Country Link
US (2) US20220133841A1 (fr)
EP (1) EP3870221A1 (fr)
JP (2) JP2022508952A (fr)
KR (1) KR20210080390A (fr)
CN (1) CN113226368A (fr)
AU (1) AU2019365804B2 (fr)
BR (1) BR112021007083A2 (fr)
CA (1) CA3115828A1 (fr)
MA (1) MA53986A (fr)
MX (2) MX2021004366A (fr)
SG (1) SG11202103972SA (fr)
TW (1) TW202034943A (fr)
WO (1) WO2020086506A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045114A1 (fr) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulateurs de l'activite du complement
US12558398B2 (en) 2019-06-04 2026-02-24 Ucb Holdings, Inc. Inflammatory disease treatment with complement inhibitors
US20220370548A1 (en) 2019-09-12 2022-11-24 Ra Pharmaceuticals, Inc. Neurological disease treatment with complement inhibitors
WO2023215587A1 (fr) 2022-05-05 2023-11-09 UCB Biopharma SRL Traitement de la myasthénie grave avec du zilucoplan
CA3256963A1 (fr) 2022-05-05 2023-11-09 Ra Pharmaceuticals, Inc. Traitement de la myasthénie grave avec zilucoplan
JPWO2024248042A1 (fr) 2023-05-29 2024-12-05

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101503540B1 (ko) * 2006-09-05 2015-03-17 알렉시온 파마슈티칼스, 인코포레이티드 항체 매개된 신경병증의 치료를 위한 방법과 조성물
WO2010025510A1 (fr) 2008-09-03 2010-03-11 Xenome Ltd Bibliothèques de conjugués peptidiques et leurs méthodes de fabrication
HUE045646T2 (hu) 2014-06-12 2020-01-28 Ra Pharmaceuticals Inc Komplement aktivitás modulálása
WO2016123371A1 (fr) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulateurs d'activité du complément
EP3934675A2 (fr) * 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Modulateurs d'activité du complément
CA3137895A1 (fr) * 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions et methodes de modulation de l'activite du complement
US12558398B2 (en) * 2019-06-04 2026-02-24 Ucb Holdings, Inc. Inflammatory disease treatment with complement inhibitors

Also Published As

Publication number Publication date
AU2019365804B2 (en) 2026-04-02
CA3115828A1 (fr) 2020-04-30
CN113226368A (zh) 2021-08-06
US20220133841A1 (en) 2022-05-05
MX2021004366A (es) 2021-08-16
JP2025011136A (ja) 2025-01-23
BR112021007083A2 (pt) 2021-08-03
AU2019365804A1 (en) 2021-05-20
KR20210080390A (ko) 2021-06-30
JP2022508952A (ja) 2022-01-19
WO2020086506A1 (fr) 2020-04-30
MX2026001031A (es) 2026-03-02
SG11202103972SA (en) 2021-05-28
EP3870221A1 (fr) 2021-09-01
US20250032574A1 (en) 2025-01-30
TW202034943A (zh) 2020-10-01

Similar Documents

Publication Publication Date Title
EP3419633A4 (fr) Traitement des pathologies oculaires allergiques avec des cyclodextrines
IL276383A (en) Treatment of ophthalmological diseases
EP3720553C0 (fr) Dispositif de photobiomodulation destiné au traitement d'une maladie rétinienne
IL262608A (en) Combination treatment of ocular inflammatory disorders and diseases
EP3634442A4 (fr) Méthodes de traitement et de prévention de maladies
EP3658139A4 (fr) Méthodes de traitement de maladies hépatiques
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3866779A4 (fr) Traitement de maladies neurologiques
EP3273955A4 (fr) Traitement de maladies respiratoires
EP3503903A4 (fr) Traitement ascaroside de maladies auto-immunes et inflammatoires
EP3866777A4 (fr) Polythérapie pour le traitement de maladies inflammatoires
MA42930A (fr) Traitement de maladies neurodégénératives
EP3737363A4 (fr) Méthodes de traitement de maladies inflammatoires chroniques
EP3664789A4 (fr) Méthodes de traitement de maladies et de lésions des nerfs
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP3344258A4 (fr) Traitement de maladies auto-immunes et de maladies auto-inflammatoires
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
EP3735209A4 (fr) Traitement de la progression de la myopie
EP3481411A4 (fr) Traitement du glaucome et d'autres maladies oculaires
EP3727369A4 (fr) Test théragnostique pour le traitement antifongique de maladies inflammatoires
EP3891500A4 (fr) Méthodes de détection, de prévention, d'atténuation et de traitement de maladies neurologiques
GB201805100D0 (en) Treatment of sarcopenic diseases
EP3324890A4 (fr) Traitement du glaucome oculaire par l'intermédiaire d'implants intracamérulaires
EP3846855A4 (fr) Blocage du cd47 avec inhibition de la parp pour le traitement de maladies
MA52495A (fr) Nouveau traitement de maladies pulmonaires interstitielles